International Journal of Stem Cells

  • 제12권2호
  • /
  • Pages.195-205
  • /
  • 2019
  • /
  • 2005-3606(pISSN)
  • /
  • 2005-5447(eISSN)
한국줄기세포학회 (Korean Society for Stem Cell Research)
권호 표지
DOI QR코드

DOI QR Code

Efficacies of Stem Cell Therapies for Functional Improvement of the β Cell in Patients with Diabetes: A Systematic Review of Controlled Clinical Trials

  • Hwang, Gyudeok (The Catholic University of Korea, Catholic Medical Center) ;
  • Jeong, Hyunsuk (Department of Preventive Medicine, College of Medicine, The Catholic University of Korea) ;
  • Yang, Hae Kyung (Cell and Gene Therapy Products Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety) ;
  • Kim, Hun-Sung (Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Hong, Hanter (The Catholic University of Korea, Catholic Medical Center) ;
  • Kim, Na Jin (Medical Library, The Catholic University of Korea) ;
  • Oh, Il-Hoan (Catholic High-Performance Cell Therapy Center & Department of Medical Life Science, College of Medicine, The Catholic University of Korea) ;
  • Yim, Hyeon Woo (Department of Preventive Medicine, College of Medicine, The Catholic University of Korea)
  • 투고 : 2018.09.04
  • 심사 : 2019.02.11
  • 발행 : 2019.07.31
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: This study was performed to investigate whether stem cell therapy enhances β cell function by meta-analysis with proper consideration of variability of outcome measurements in controlled trial of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) patients. Methods: A systematic search was performed from inception to January 2018 in PubMed, EMBASE, and Cochrane databases. β cell function was assessed by stimulated C-peptide, fasting C-peptide, normal glycosylated hemoglobin levels (HbA1C), and exogenous insulin dose patterns. The quality of the studies were assessed by both the Cochrane Collaboration's Risk of Bias (ROB) for Randomized controlled trials and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized controlled trials. Results: From the selected final 15 articles, total of 16 trials were analyzed. There were 6 T1DM trials (total 153 cases) and 10 T2DM trials (total 457 cases). In T2DM patients, the changes in stimulated C-peptide, HbA1c, and exogenous insulin dose versus baseline showed a favorable pattern with a significant heterogeneity in stem cell therapy. In T1DM, there was no significant difference between control group and stem cell therapy group in three indicators except for HbA1c. Most of the studies were rated as having high risk of bias in the quality assessment. Conclusions: The stem cell therapy for DM patients is not effective in T1DM but seems to be effective in improving the β cell function in T2DM. However the observed effect should be interpreted with caution due to the significant heterogeneity and high risk of bias within the studies. Further verification through a rigorously designed study is warranted.

키워드

과제정보

This research was supported by a grant (18172MFDS182) from the Ministry of Food & Drug Safety in 2018. The Ministry of Food & Drug Safety had no further role in areas of study design, collection, Ms. Songui Choi conducted Chinese translation into Korean of the reference written in Chinese.

참고문헌

  1. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998;128:517-523
  2. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-4058
  3. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249-1258
  4. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998;15:290-296 https://doi.org/10.1002/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M
  5. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 2003;96:281-288 https://doi.org/10.1093/qjmed/hcg040
  6. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297: 1568-1576 https://doi.org/10.1001/jama.297.14.1568
  7. Couri CE, de Oliveira MC, Simoes BP. Risks, benefits, and therapeutic potential of hematopoietic stem cell transplantation for autoimmune diabetes. Curr Diab Rep 2012;12: 604-611 https://doi.org/10.1007/s11892-012-0309-0
  8. Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Krol M, Boguradzki P, Jedynasty K, Franek E, Wiktor-Jedrzejczak W. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 2011;46:562-566 https://doi.org/10.1038/bmt.2010.147
  9. Estrada EJ, Valacchi F, Nicora E, Brieva S, Esteve C, Echevarria L, Froud T, Bernetti K, Cayetano SM, Velazquez O, Alejandro R, Ricordi C. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant 2008;17:1295-1304 https://doi.org/10.3727/096368908787648119
  10. Bhansali S, Dutta P, Kumar V, Yadav MK, Jain A, Mudaliar S, Bhansali S, Sharma RR, Jha V, Marwaha N, Khandelwal N, Srinivasan A, Sachdeva N, Hawkins M, Bhansali A. Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: a randomized, placebo-controlled comparative study. Stem Cells Dev 2017;26:471-481 https://doi.org/10.1089/scd.2016.0275
  11. Ghodsi M, Heshmat R, Amoli M, Keshtkar AA, Arjmand B, Aghayan H, Hosseini P, Sharifi AM, Larijani B. The effect of fetal liver-derived cell suspension allotransplantation on patients with diabetes: first year of follow-up. Acta Med Iran 2012;50:541-546
  12. Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP; D-Cure Workshop. Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev 2009;25:694-704 https://doi.org/10.1002/dmrr.1002
  13. Greenbaum CJ, Harrison LC; Immunology of Diabetes Society. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003;52:1059-1065 https://doi.org/10.2337/diabetes.52.5.1059
  14. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264 https://doi.org/10.2337/diabetes.53.1.250
  15. Wang ZX, Cao JX, Li D, Zhang XY, Liu JL, Li JL, Wang M, Liu Y, Xu BL, Wang HB. Clinical efficacy of autologous stem cell transplantation for the treatment of patients with type 2 diabetes mellitus: a meta-analysis. Cytotherapy 2015; 17:956-968 https://doi.org/10.1016/j.jcyt.2015.02.014
  16. El-Badawy A, El-Badri N. clinical efficacy of stem cell therapy for diabetes mellitus: a meta-analysis. PLoS One 2016; 11:e0151938 https://doi.org/10.1371/journal.pone.0151938
  17. Cao JX, Zhao YQ, Ding GC, Li JL, Liu YS, Wang M, Xu BL, Liu JL, Wang ZX. Evaluation of the clinical efficacy of stem cell transplantation in patients with type 1 diabetes mellitus. Int J Clin Exp Med 2016;9:19034-19051
  18. Ulyanova O, Taubaldieva Z, Tuganbekova S, Saparbayev S, Kim N, Trimova R, Kozina L, Shaimardanova G. Leptin level in patients with type 2 diabetes mellitus after fetal pancreatic stem cell transplant. Exp Clin Transplant 2016;14 (Suppl 3):45-47
  19. Chen P, Huang Q, Xu XJ, Shao ZL, Huang LH, Yang XZ, Guo W, Li CM, Chen C. [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus]. Chin J Int Med 2016;55:349-354.
  20. Wu Z, Cai J, Chen J, Huang L, Wu W, Luo F, Wu C, Liao L, Tan J. Autologous bone marrow mononuclear cell infusion and hyperbaric oxygen therapy in type 2 diabetes mellitus: an open-label, randomized controlled clinical trial. Cytotherapy 2014;16:258-265 https://doi.org/10.1016/j.jcyt.2013.10.004
  21. Sood V, Bhansali A, Mittal BR, Singh B, Marwaha N, Jain A, Khandelwal N. Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods. World J Diabetes 2017;8:381-389 https://doi.org/10.4239/wjd.v8.i7.381
  22. Skyler JS, Fonseca VA, Segal KR, Rosenstock J; MSB-DM003 Investigators. Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care 2015;38:1742-1749 https://doi.org/10.2337/dc14-2830
  23. Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S, Wang Y. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J 2013;60:347-357 https://doi.org/10.1507/endocrj.EJ12-0343
  24. Hu J, Wang Y, Gong H, Yu C, Guo C, Wang F, Yan S, Xu H. Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes. Exp Ther Med 2016;12:1857-1866 https://doi.org/10.3892/etm.2016.3544
  25. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR, Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol Blood Marrow Transplant 2013;19:1126-1129 https://doi.org/10.1016/j.bbmt.2013.04.011
  26. Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 2015;64:587-592 https://doi.org/10.2337/db14-0656
  27. Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, Wu W, Luo F, Wu C, Pugliese A, Pileggi A, Ricordi C, Tan J. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. diabetes care. 2016;39:149-157 https://doi.org/10.2337/dc15-0171
  28. Bhansali A, Asokumar P, Walia R, Bhansali S, Gupta V, Jain A, Sachdeva N, Sharma RR, Marwaha N, Khandelwal N. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant 2014;23:1075-1085 https://doi.org/10.3727/096368913X665576
  29. Giannopoulou EZ, Puff R, Beyerlein A, von Luettichau I, Boerschmann H, Schatz D, Atkinson M, Haller MJ, Egger D, Burdach S, Ziegler AG. Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: a non-randomized, controlled trial. Pediatr Diabetes 2014;15:100-109 https://doi.org/10.1111/pedi.12072
  30. Hu J, Li C, Wang L, Zhang X, Zhang M, Gao H, Yu X, Wang F, Zhao W, Yan S, Wang Y. Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus. Endocr J 2012;59:1031-1039 https://doi.org/10.1507/endocrj.EJ12-0092
  31. Hill NR, Levy JC, Matthews DR. Expansion of the homeostasis model assessment of β-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2. Diabetes Care 2013;36:2324-2330 https://doi.org/10.2337/dc12-0607
  32. King AB. Misled by the morning "fasting" plasma glucose. J Diabetes Sci Technol 2015;9:1342-1345 https://doi.org/10.1177/1932296815586425
  33. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013;30:803-817 https://doi.org/10.1111/dme.12159
  34. Hussain MA, Theise ND. Stem-cell therapy for diabetes mellitus. Lancet 2004;364:203-205 https://doi.org/10.1016/S0140-6736(04)16635-X
  35. Huss R, Xiangwei X, Heimberg H. [Adult stem cells regenerate the endocrine pankreas and normalize hyperglycaemia and insulin production in diabetic mice]. Verh Dtsch Ges Pathol 2005;89:184-190.
  36. Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, Zhang Y, Diao Y, Li Y, Chen Y, Sun X, Fisk MB, Skidgel R, Holterman M, Prabhakar B, Mazzone T. Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med 2012;10:3 https://doi.org/10.1186/1741-7015-10-3
  37. Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Zhou H, Yin Z, Chen Y, Zhang Y, Wang S, Shen J, Thaker H, Jain S, Li Y, Diao Y, Chen Y, Sun X, Fisk MB, Li H. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Med 2013; 11:160 https://doi.org/10.1186/1741-7015-11-160
  38. Cantu-Rodriguez OG, Lavalle-Gonzalez F, Herrera-Rojas MA, Gutierrez-Aguirre CH, Mancias-Guerra C, Jaime-Perez JC, Gonzalez-Llano O, Zapata-Garrido A, Villarreal-Perez JZ, Gomez-Almaguer D. Autologus hematopoietic stem cell transplant in type 1 diabetes mellitus in a nonmyeloablative and outpatient setting. Blood 2014;124:1191 https://doi.org/10.1182/blood.V124.21.1191.1191

피인용 문헌

  1. Diabetes Mellitus Is a Chronic Disease that Can Benefit from Therapy with Induced Pluripotent Stem Cells vol.21, pp.22, 2019, https://doi.org/10.3390/ijms21228685
  2. Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study vol.11, pp.1, 2020, https://doi.org/10.1186/s13287-020-01996-x
  3. Stem Cell-Based Clinical Trials for Diabetes Mellitus vol.12, 2019, https://doi.org/10.3389/fendo.2021.631463
  4. Where Do We Stand in Stem Cell Therapy for the Management of Diabetes Mellitus?-A Scientometric Research Trend Analysis from 1990 to 2020 vol.8, pp.11, 2019, https://doi.org/10.3390/bioengineering8110159